Virpax Pharmaceuticals, Inc. - Common Stock (NQ:VRPX)

0.6695 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Get insights into the top gainers and losers of Friday's pre-market session. ↗

February 28, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

US Stocks Likely To Open Higher Following A Sell-Off, 'This Choppy Start To 2025 Isn't Abnormal. Don't Panic,' Says Expert Highlighting Seasonal Weakness In The First Quarter After Elections ↗

February 28, 2025

U.S. stock futures rose on Friday following Thursday's sell-off. Futures advanced except the small-cap gauge Russell 2000.

Via Benzinga

These stocks are moving in today's after hours session ↗

February 27, 2025

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

February 27, 2025

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Unusual volume stocks in Tuesday's session ↗

February 18, 2025

Let's have a look at the stocks with an unusual volume in today's session.

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

February 18, 2025

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 18, 2025

Via Benzinga

What's going on in today's after hours session ↗

February 14, 2025

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Check out the stocks that are attracting the most attention and driving market activity. ↗

February 14, 2025

Let's dive into the action on the US markets on Friday. Here are the most active stocks that are driving the market today.

Via Chartmill

Unusual volume stocks in Friday's session ↗

February 14, 2025

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.

Via Chartmill

Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate ↗

February 14, 2025

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.

Via Benzinga

Friday's session: gap up and gap down stocks ↗

February 14, 2025

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

Top movers in Friday's pre-market session ↗

February 14, 2025

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 14, 2025

Via Benzinga

Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

February 14, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

February 13, 2025

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

February 13, 2025

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

January 31, 2025

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering

January 30, 2025

From Spartan Capital Securities, LLC

Via GlobeNewswire

Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

January 30, 2025

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants

January 28, 2025

From Virpax Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 06, 2024

Via Benzinga

Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

December 06, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 25, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 22, 2024

Via Benzinga

Why Is Virpax Pharmaceuticals Stock Gaining On Friday? ↗

November 22, 2024

Virpax Pharmaceuticals shares are up 59.4% after announcing an extended collaboration with NCATS to advance its NES100 pain management candidate. Virpax also announced results from a minipig Dose Range...

Via Benzinga

Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™

November 22, 2024

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket ↗

November 22, 2024

Via Benzinga

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative

November 21, 2024

From Virpax Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.